Day One (DAWN) - Quarterly EPS earnings growth

Official company branding of Day One Biopharmaceuticals (DAWN)

Day One (DAWN) dominates the pediatric brain tumor therapy niche due to the uniqueness of Ojemda and FDA support. This quarterly earnings per share chart illustrates the current trend, where 67.90 determines this parameter level. The company is scaling sales and expanding its portfolio with new molecules, although high commercialization costs are creating temporary cash flow instability.

Day One Biopharmaceuticals (DAWN) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 05/09/2026

Analytical breakdowns for Day One

- market value and analyst target forecast:
Price Chart Day One Biopharmaceuticals|DAWN - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Day One Bio|DAWN - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Day One Biopharmaceuticals|DAWN - Total Stockholders' Equity|Market Value to Book Value Ratio dayonebio.com|DAWN - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Day One|DAWN - Long-Term Liabilities to Capital|Short-Term Debt to Capital Day One|DAWN - Company Total Indebtedness|Debt to Book Value Day One Bio|DAWN - Long-Term Debt|Company Current Liabilities Day One Biopharmaceuticals|Quick Liquidity Indicator dayonebio.com
- earnings and market multiples details:
DAWN - Profit After Payment of Taxes|Projected Future Earnings Day One|DAWN - Company Value to Net Income|Forward P/E Multiple Day One Bio|DAWN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Day One Bio|DAWN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Day One Biopharmaceuticals|DAWN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months dayonebio.com|DAWN - Earnings per share trend in current year|Expected earnings per share growth for next year Day One
Fundamental company analysis:Day One Biopharmaceuticals, DAWN
Manufactured product of Day One Biopharmaceuticals Inc

The quarterly earnings per share (EPS) growth rate measures net income dynamics relative to the previous period. This metric assesses the efficiency of business capitalization and its ability to generate cash flow. By analyzing the quarterly EPS growth valuation, an investor determines the sustainability of dividend potential. For Day One (DAWN), this indicator reflects the commercial success of implementing targeted therapies. Profit growth here depends directly on the scale of insurance reimbursement for the treatment of rare tumors.

Analysis of competing companies

Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Monopar Corp (MNPR)|Year-over-year earnings per share growth for the last twelve months Inhibrx Biosciences (INBX)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc. FENC|Heron - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Coherus Biosciences|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla Corp BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology Holdings)|CTXR (citiuspharma.com) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (biolinerx.com)|Can-Fite BioPharma Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com